ProMIS Neurosciences Overview, updated July 29, 2020

1

Toronto Stock Exchange (TSX) ticker: PMN OTCQB ticker: ARFXF

Forward looking statement: safe harbor

This slide deck may contain certain forward-looking information. Such information involves known and unknownrisks, uncertainties and other factors that may cause actual results, performance or achievements to bematerially different from those implied by statements herein, and therefore these statements should not beread as guarantees of future performance or results. All forward-looking statements are based on theCompany’s current beliefs as well as assumptions made by and information currently available to it as well asother factors. Readers are cautioned not to place undue reliance on these forward-looking statements, whichspeak only as of the date of this slide deck. Due to risks and uncertainties, including the risks and uncertaintiesidentified by the Company in its public securities filings available online at www.sedar.com. Actual events maydiffer materially from current expectations. The Company disclaims any intention or obligation to update orrevise any forward-looking statements, whether as a result of new information, future events or otherwise.

2

ProMIS Neurosciences overview

• Unique technology platform, rapid, cost-effective value creation

• COVID serology test – current test among industry best, goal to create a 2nd iteration that can confirm immunity using ProMIS proprietary reagents

§ Expected need for MMs – 100’s of MM’s of accurate immunity tests

• Alzheimer’s and dementia mission and portfolio: Treat – Detect – Prevent§ PMN310 potential best in class therapy, scientific superiority to likely first in class Biogen’s aducanumab

§ Mid-2021 expected approval for aducanumab

• Entered rapidly growing AD/dementia screening and diagnosis market – JV with leading diagnostic lab

• Initial proof of concept for Alzheimer’s vaccine – ramping up vaccine development

• Numerous near-term catalysts

• Highly experienced management team and Boards

3

Unique proprietary platform offers multiple opportunities for value creation: timelines contingent on availability of adequate capital

4

Q3 2020 Q4 2020 Q3 2021Q1 2021 Q2 2021 Q4 2021

COVID-19 Serology/Immunity

Assay

PMN310 Best in class AD

antibody therapy

Neurodegenerative Disease

Diagnostics/Assays

Alzheimer’s Vaccine

Scientific evaluations and assay

developmentCOVID-19 Serology/Immunity Assay potential revenue – multiple sources

PMN310 IND enabling work (CMC – manufacturing; GLP Toxicology) PMN310 Phase 1 clinical trial in AD

patients – biomarker and clinical endpoints

Equipment purchase and assay validation

Neurodegenerative disease: potential detection assay revenue, potential diagnostic revenue

Develop vaccine using ProMIS proprietary peptide antigens, preclinical validation, initiate IND enabling work

Therapy Development Diagnostic Development Diagnostic Revenue

ProMIS unique technology platform: the key to unlocking value

5

YAntibody

Conformational Epitope

Toxic Protein or virus

Antibodies bind to targets called EPITOPES ( )which have a specific conformation or shape

ProMIS unique technology platform: the key to unlocking value

6

YAntibody

Conformational Epitope

Toxic Protein or virus

Antibodies bind to targets called EPITOPES ( )which have a specific conformation or shape

Peptide Antigen

Predict epitope including shape: Supercomputer Computations

Design and create an exact

replica

ProMIS has unique capability to predict epitopes including their shape and make precise replicas – peptide antigens

Highly Specific Peptide antigensMake “best in class”

- Antibody Therapies- Diagnostics- Vaccines

Y

ProMIS portfolio of therapies and diagnostics is based on the unique platform

7

PMN310“Best in class” Alzheimer’s Tx

Conformational Epitope

Toxic Oligomers of amyloid

Epitopes for neutralizing antibodies

Serology Assaydetecting neutralizing

antibodies:Immunity

Alzheimer’s Disease

Coronavirus

RBD1 of spike

COVID Serology

1RBD = Receptor binding domain of spike protein

COVID-19 pandemic: need for serology assays that can confirm protective immunity

• Situation• Currently limited, evolving understanding of human immune response to COVID-19 exposure• Historically rapid vaccine development; vaccines will be approved with very little information about

variability and durability of immune response• Numerous existing serology assays provide accurate information about exposure to COVID-19,

including Roche, Siemens, ProMIS/BCNI• But exposure does not necessarily mean immunity, the ability to resist re-infection

• ProMIS approach to evaluation of protective immunity• ProMIS peptide antigens (n=18) identified on RBD of COVID-19 virus• Peptide antigens may represent targets for neutralizing antibodies• Test sera from patients exposed to COVID-19 for neutralizing activity in laboratory assays with live

coronavirus or pseudo-coronavirus• Goal: A high throughput, cost effective assay that accurately correlates with gold standard

tests of antibody-based immunity

8

There is a way to measure antibody immunity…but much too expensive and cumbersome…ProMIS/BCNI are working to create a high volume, cost-effective assay

COVID-19 Immunity is complex• Cellular (T-cells) vs humoral (antibodies)• High variability• Quality of immunity after COVID infection• Quality of immunity after vaccination• Duration of immunity (months, years?)• Immunity in elderly, other subgroups• Infection may not lead to immunity from re-

infectionvProMIS assay to provide answers

9

YY

YYY Y Y Y

Y Y Y YBlood sample

Do antibodies in the blood sample bind COVID-19 antigen?

Do neutralizing antibodies bind ProMIS peptide epitopes?

YESPatient has

been exposed

YESPatient is immune

PROMIS ASSAY

If results of neutralization assay based on ProMIS proprietary antigens are positive in Q4 2020, ProMIS may seek revenue in several ways

• Offer ProMIS unique peptide antigens in multiple non-exclusive licenses to multiple global diagnostics players (Roche, Siemens, etc) ; $2-$6 per test potential

• Deals with vaccine manufacturers for serology testing in clinical trials and post-marketing• Collaborate with a SPR instrument company (Danaher, Bruker), to seek EUA (Emergency

Use Authorization) approval for our assay on a high throughput SPR platform• Serology testing for large projects e.g. province of Ontario, BC• Potential revenue opportunity Q4/2020, 2021

10

COVID serology testing opportunity

11

Roche Abbott Siemens Ortho

- Major global players in current COVID serology, all sell test kits to diagnostics labs- Common to validate reagents on SPR (our platform), then sell reagents on a cost/test basis to them- Goal: create an assay that provides information about antibody immunity useful enough so thatnone of the four want to be left out

Abbott CEO Robert Ford in FORBES, July 17“As vaccines become available, we would anticipate continued surveillance testing to monitor and assess for both natural and vaccine related immune response, which would be followed by a steady state of ongoing monitoring and tracking of vaccineprotection…..that’s where I think we will see an increase in serology and antibody testing. I see that that’s going to be anopportunity for us and other companies that have the antibody test, I see that as being a real demand driver on the serology side”

Despite two active decades of clinical trials, there are not yet any approved disease modifying therapies → a pressing, unmet medical need

12

Alzheimer’s disease profoundly impacts patients, caregivers and society

“Will Bankrupt Medicareif Therapy is not developed”

Direct and Indirect Costs Today in the US $500BB….

…. and the number is tripling by 2030….

AD characterized by brain accumulation of misfolded proteins:• Extracellular Amyloid Beta (Aβ), then• Intracellular Tau (Neurofibrillary Tangles)Toxic oligomeric species lead to:• Synaptic dysfunction and loss• Degeneration and death of neurons• Neuroinflammation• Brain atrophy

13

ProMIS Neurosciences: an integrated strategy to address Alzheimer’s disease

TreatDetect Prevent

ProMIS/BCNI Joint Venture

Create state-of-the-art diagnostic

clinical platform for AD and other

neurodegenerative diseases

PMN310Provide best in class

anti-amyloid therapeutic

antibody that binds only toxic

oligomers, not monomer or plaque

Amyloid VaccineDevise safe, effective anti-amyloid and/or anti-tau vaccines to

induce a specific immune response

against toxic oligomers

Aβ accumulation is slow and protracted, taking 20 to 30 years before cognitive symptomsThis lengthy pre-symptomatic phase of AD provides a substantial opportunity to detect neuropathology,

prevent further brain abnormalities and treat patients before symptoms appear

Using ProMIS proprietary epitope prediction platform

14

Billions of neurons are killed leading to the Alzheimer’s (AD) brain

1 Reviewed in Bloom 2014, JAMA Neurol

Healthy Brain Brain with Mild Cognitive Impairment

Brain with AD1

15 years pre-symptomatic 5 years MCI 10 years Alzheimer’s

Toxic oligomers of amyloid cause tau to become toxic, increase neuroinflammation, neurons and synapses die

Neurofilament light (NfL) increases as neurons die at faster rate, P-tau181 increases as amyloid oligomers increase toxic tau oligomers

Alzheimer’s disease: soluble toxic Aβ oligomers – not plaque or monomers – are the most neuropathogenic Aβ species

• Synapse abnormalities and memory impairment correlate poorly with plaque burden in human and mouse AD1,2

• Aβ monomers and Aβ insoluble fibrils (plaque) have little or no demonstrable toxicity in vitro or in vivo3-5

• Soluble Aβ oligomers show the highest degree of neurotoxicity6

• Toxicity in primary neuron cultures and brain slices3,5,7-9

• Induction of cognitive impairment in rodents3,4,10

151Jacobsen et al, 22006, PNAS; 2Brier et al, 2016, Science Trans Med; 3Shankar et al, 2008, Nature Med; 4Cleary et al, 2005, Nature Neuroscience; 5Hong et al, 2016, Science; 6Benilova et al, 2012, Nature Neuroscience - Review; 7Lacor et al, 2007, J Neuroscience; 8Jin et al, 2011, PNAS; 9Lauren et al, 2009, Nature; 10Balducci et al, 2010, PNAS

Synaptotoxicity of human Ab oligomers on hippocampal neurons in vitro7

5min 6h 24h 24h control

Monomers Oligomers Fibrils

Normal Monomers Oligomers Fibrils

Ab species injected

In vivo impairment of recognition memory by Ab oligomers, not monomers and not fibrils10

PMN310: an anti-Aβ-oligomer antibody with strong potential to demonstrate best-in-class characteristics

Biogen’s aducanumab EMERGE study validates the amyloid hypothesis

Aducanumab and BAN2401 are only partially selective for amyloid oligomers

• Aducanumab (phase 3) and BAN2401 (phase 2) showed modest but meaningful efficacy in reducing cognitive worsening

• Both significantly bind amyloid plaque → ARIA-E (patchy brain swelling)• Neither bind monomer (the physiologic amyloid species)

PMN310 is a next-generation, best-in-class anti-amyloid therapy• Highly selective for only toxic oligomers• Dose will not be limited by off-target binding or side effects

• Does not bind monomer• Does not bind plaque → likely no ARIA-E

• All dosed PMN310 will focus on neutralizing toxic oligomers → potential greater clinical efficacy

16

Aβ amino acids 13-16 (HHQK)A unique, Aβ oligomer specific epitope targeted by PMN310

There are three forms of amyloid, choosing the correct target is critical….

17

Monomer – Important for brain health

Plaque – usually present, but no significant role in

disease

Toxic oligomers –thousands of scientific

studies showing neurotoxicity

Two drugs: Biogen’s aducanumab and EISAI’s BAN2401 partially selective FOUR OUT OF FOUR POSITIVE*(Two Phase 2 trials, one Phase 3 program*)!!! DOSE-LIMITING TOXICITY side effect ARIA-E** due to plaque binding !!!

* Using Biogen’s presentation of patients consenting to V4 amendment, receiving 10mg dosing** ARIA-E (Amyloid Related Imaging Abnormality- Edema) also known as brain swelling

Monomer – Important for brain health

Plaque – usually present, but no significant role in

disease

Toxic oligomers –thousands of scientific

studies showing neurotoxicity

Monomer – Important for brain health

Plaque – usually present, but no significant role in

disease

Toxic oligomers –thousands of scientific

studies showing neurotoxicity

Monomer – Important for brain health

Plaque – usually present, but no

significant role in disease

Toxic oligomers –thousands of scientific

studies showing neurotoxicity

4 programs/13 phase 2 and 3 clinical trials non-selectively targeting all forms of amyloid, wasted too much ammunition on abundant monomer to be effective

All negative

10 programs/25 phase 2 and 3 clinical trials targeting monomer

All negative

Forms of Amyloid

AmyloidBinding

profile of clinical

programs

Four positive trials…partially selective antibodies…higher dose over long duration leads to better outcomes, but all limited by patchy brain swelling (ARIA-E)

18

Biogen Ph1b “PRIME” December 2014

Eisai BAN2401 Phase 2July 2018

Biogen pivotal EMERGEDec 2019*

Biogen pivotal ENGAGEDec 2019**

* Final Intent-to-treat data set ** Post-protocol version 4 data set

19

The three largest products in industry history were not first in class, but “best in class” – the inventors identified improvements to existing drugs

ProMIS following the “best in class” playbook with PMN310• Improved selectivity for toxic

oligomers• No binding to plaque = Lower

risk of ARIA-E = Better safety• Ability to safely dose higher• No “waste of ammunition” on

non-toxic amyloid -> Greater efficacy

Lipitor Humira Sovaldi/HarvoniCholesterol RA, Crohn’s Hepatitis C1996 2003 2014

PeakSales $BB’s

$12BB$16BB

$25BB

Binding the right form of toxic oligomer is critical……

20

Aducanumab (Biogen)• Phase 2 & 3 success• ARIA-E side effect

Solanezumab (Eli Lilly)• Phase 2 failure• Phase 3 failure

Bapineuzumab (Pfizer)• Phase 2 failure• Phase 3 failure• ARIA-E side effect

MONOMERS- binding wastestherapeutic ammunition

FIBRILS (Plaque)- binding wastestherapeutic ammunition- contributes to ARIA-Eside effect

OLIGOMERS*- the right target

PMN310• Selective binding to

oligomers-> Expected improvement in

efficacy & safety

* Synthetic oligomers

21

ARIA-E associated with aducanumab, BAN2401 & bapineuzumab; PMN310 lack of binding to Aβ plaque strongly suggests a potential safety advantage

Aducanumab PMN310

Plaque binding

Vascular deposit binding

No binding to plaque or vascular deposits

Most likely no ARIA-E*

* ARIA-E (Amyloid Related Imaging Abnormality- Edema) also known as brain swelling

Humanize

d PMN310

Aducanumab

Bapineu

zumab

huIgG10

10

20

30

40

50B

indi

ng R

espo

nse

(RU

)

PMN310 shows superior binding to toxic oligomers from human AD brains vs other antibodies directed against amyloid-beta

22

• Binding of antibodies to the toxic oligomer-enriched LMW fraction of soluble human AD brain extract was evaluated by surface plasmon resonance (SPR)

• Results representative of over 10 SPR runs with extracts from 11 different AD brains

• huIgG1 = Background control

Source for comparative reagents: Creative Biolabs

AbO +/- MabNovel Object Recognition Assay

• Control mice remember a familiar object when re-exposed to it and spend more time exploring a new object

• Oligomer-injected mice lose the ability to discriminate between known and novel objects and spend equivalent amounts of time exploring both

7 days

-0.2

0.0

0.2

0.4

0.6

Vehicle AβOPMN310+ vehicle

PMN310+ AβO

Dis

crim

inat

ion

Inde

x

#

* *

Discrimination index = (Time exploring new object – time exploring familiar object) / total exploration timeResults press released January 9, 2017, www.promisneurosciences.com 23

N=12 per arm, *different from AβO (p < 0.05), #different from vehicle (p <0.05)

Administration of PMN310 to mice: prevents loss of short-term memory formation caused by toxic oligomers, by saving mouse neurons

THE RESULTSTHE EXPERIMENT• Mice are tested for discriminating objects after

brain injection of:• Buffer (vehicle) - normal response • Toxic Aβ oligomer• PMN310 and buffer (vehicle)• PMN310 and Aβ Oligomer

PMN310: potential for value-creating clinical data in the near term - likely positive market developments could amplify PMN value

24

ProMIS Final IND enabling work

2020

AD in Down Syndrome - prevention, treatment, or both: Biomarker and

clinical endpoint readout

Sporadic AD Phase 1: 3 month Pbo control, 9 month extension, MAD design

2021 2022

Potential Approval Path:AD in Down Syndrome

AducanumabFiling

AducanumabApproval

Aducanumab Launch and Market Development- Reimbursement, Med Ed: ARIA-E screening

BAN2401 Ph 3 data

• Recent advances in blood-based biomarkers may allow ProMIS to detect an objective treatment signal as early as Phase 1, potentially providing rapid & cost-effective proof-of-concept

ProMIS plans to use biomarkers in its first clinical study, which could show a disease modifying treatment effect at a cost of $5MM-$10MM

25

BloodNfL

100*

* 100 = patient baseline value

Months1260

Placebo/ Large natural history dataset

3 mg/kg

10 mg/kg

20 mg/kg

40 mg/kg

80 mg/kg

Placebo dataset as an historical control

Potential for meaningful datain 6-12 months from trial start…

Potential biomarkers:

NfL – Neuronal Loss

P-tau181 - tau toxicity

Others

Dose escalation design: 3-month placebo-control, then 9-month open-label extension

Alzheimer’s/Dementia screening, diagnosis, and disease monitoring

26

Historical: AD diagnosis at autopsy

Recent advance:A/T/N

Amyloid PET

Tau PET

Cortical MRI

$10,000 - $15,000

Future Vision A/T/N

NfLBlood based

P-tau181Blood based

~$100

…Plus proprietary assays

TDP43 , Alpha Synuclein- Differential diagnosis

Other assays – overall algorithm

ProMIS/BCNI Joint Venture to build a diagnostic revenue base

• Significant progress over past several yrs. to advance a more precise diagnosis of AD• Introduction of A/T/N (amyloid/tau/neurodegeneration) criteria 2 years ago offered an unbiased approach for

objective biological diagnosis of AD • However, the A/T/N diagnostic approach, until recently, required either costly PET and MRI scan assessments or

invasive lumbar puncture to measure specific biomarkers in cerebrospinal fluid (CSF)

• Blood levels of NfL (neurofilament light chain) and P-tau181 (phosphorylated tau181)• Provide equally precise A/T/N characterization as imaging or CSF measurements, and can thus offer convenient, cost-

effective and objective detection and monitoring of the AD process

• JV/collaboration to first offer existing blood-based assays for NfL and P-tau181

• Further assays to be added potentially incorporating ProMIS’ proprietary peptide antigens & tests for additional neurodegenerative diseases

• ProMIS’ ultimate mission with its partner, BCNI, is to build a portfolio of assays that enables early detection and monitoring of disease progression before symptoms arise

• Discussions for screening projects have started – goal revenue in 2021, possibly Q4 2020

27

ProMIS therapeutic vaccine for Alzheimer’s disease

• Large patient population with symptomatic AD in need of effective treatment (n≥5M, USA) –> Therapeutic vaccination

• Ever greater number of individuals in the pre-symptomatic phase of the disease (potentially 40% of the population over 65, ~50M) –> Prophylactic preventative vaccine

• Vaccine approach will benefit from recent progress in the development of blood-based biomarkers of neurodegeneration to diagnoseAD and identify individuals at risk of developing disease

• ProMIS discovery platform being applied to devise a safe and effective vaccine to induce a specific immune response against toxic Ab oligomers • Identified a set of 6 conformational peptide epitopes selectively exposed on toxic Ab oligomers • All 6 peptide epitopes shown to be capable of inducing selective and protective antibodies against toxic Ab oligomers • Successful proof of concept vaccination study conducted with one of the peptides (cSNK) in a mouse model of AD (APP/PS1

mice): Neuronal protection and improvement in cognitive deficits2• Concept: multivalent vaccine with some or all 6 Ab peptides. Tau peptides recently identified could also be included.

• Immediate aims: Construct and test multivalent Ab vaccine for ability to induce a protective antibody response

281Marciani DJ, 2019, AAAS Research, https://doi.org/10.34133/2019/5341375; 2Silverman, JM et al, 2018, ACS Chem Neurosci

Benefit of vaccination with ProMIS Ab oligomer (AbO) epitope

29

Mice vaccinated with conformational Ab oligomer epitope (cSNK) coupled to KLH

PMN301,3

02,30

3,304

,305

PMN301-N

MS(1:5)

PMN302-N

MS(1:5)

PMN303-N

MS(1:5)

PMN304-N

MS(1:5)

PMN305-N

MS(1:5)

NMS-100

0

20

40

60

80

Bin

ding

Res

pons

e (R

U)

AbM(HFIP) AbM(untreated) AbO(SynAging)

Robust, sustained antibody response (SPR)

Improvement in behavioral deficits of APP/PS1 mice

Protection against synaptic damage

Biological support for multivalent vaccine approach:Greater binding with mixture of sera from mice

immunized with different AbO epitopes vs immune serum against individual peptides

Silverman et al. 2018. ACS ChemNeurosci 9: 1591-1606

AbO

SPR

HFIP Abmonomers

Untreated Abmonomers

(normal mouse serum)

ProMIS: current portfolio of antibodies selectively targeting toxic mis-folded proteins

30

Scientific Literature:mis-folded protein role

in disease pathogenesis;

role of other forms (molecular species)

Predict conformational

epitopes on target molecular species

Immunize and screen antibody candidates

for selectivity

Assess functional benefit in vitro and in vivo; assess binding strength to enriched patient biomaterial

IND enabling development

Biomarker readouts of pharmacologic

effect in Ph1

Predict Produce Prioritize Lead program early POC

Amyloid beta PMN310, ready for final IND enabling work

Alpha SynucleinSeveral leads, active

partnering discussions

TDP43 Several leads, active partnering discussions

tau Early leads, immunization ongoing , active partnering discussions

Many ongoing discovery: RACK1, DISC1, FUS, SOD1, Amylin, PrP, other

ProMIS Summary Investment Thesis

• Unique technology platform – rapid, cost-effective, differentiated

• Rapid response to COVID-19; goal to create differentiated immunity serology assay, potential near term revenue if successful

• Strategic portfolio in Alzheimer’s based on unique platform – Detect – Treat – Prevent

• PMN310 scientifically superior to likely “first in class” therapy Biogen’s aducanumab, PMN310 selective for toxic oligomers, stronger binding

• Biogen filed for regulatory approval, potential launch mid 2021, will be strong catalysts for the field, especially improved amyloid targeted therapies like PMN310

• ProMIS broad portfolio, programs targeting mis-folded versions of TDP43, alpha synuclein, tau, ongoing partnering discussions (timing affected by industry priority shift to COVID, lab closures, etc.)

• Aducanumab launch will also likely lead to dramatic growth in demand for screening and diagnosis of dementia

• ProMIS JV with BCNI will enable capitalizing on that growing demand with both established and proprietary assays

• ProMIS technology enables potential Alzheimer’s vaccine – building on early POC

31

Name

Experienced leadership team

30

Prior ExperienceTitle Years of Experience

Executive Chairman

CEO

Chief Science Officer

Chief Physics Officer

CFO

Chief Development Officer

25+

25+

25+

20

25+

25+

§ Former SVP at Genzyme, with senior roles integrating commercialization, drug development, and deal making

§ Recently the CEO of Dart Therapeutics, an Orphan Disease drug development company

§ Founder and director of Adheris, which became the largest company in the patient adherence/compliance area

§ Held positions as SVP of Strategic Product Development at SmithKline Beecham (now GSK)

§ Chief Operating Officer and Chief Medical Officer of Maxygen§ Chief Operating Officer at DART Therapeutics

§ Holds the Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases,

§ Serves as the Director of the University of British Columbia ALS Centre,

§ Awarded the Jonas Salk Prize for biomedical research in 2000

§ Professor at UBC in the Department of Physics and Astronomy since 2001§ Appointed as the Canada Research Chair in Theoretical Molecular Biophysics§ Associate member of the Genome Sciences and Technology Program, the

Bioinformatics Program, and the Institute for Applied Mathematics at the University of British Columbia

§ Founding Managing Director of Danforth Advisors§ Served as the Chief financial officer of Homology, Inc, GenePeeks,

Inc., Transkaryotic Therapies, Inc., Cidara, Inc., Apellis, Inc. and Stealth BioTherapeutics, Inc.

§ Former VP of Research at Genzyme§ Associate Immunopathologist at SmithKline Beecham where she

established an Immunotoxicology program§ Her work has resulted in over 60 scientific publications and multiple patents

Gene Williams

Elliot Goldstein

Neil Cashman

Steven Plotkin

Dan Geffken

Johanne Kaplan

James Kupiec Chief Medical Officer 25+

§ Former VP, Global Clinical Leader for Parkinson’s disease, and Clinical Head of the Neuroscience Research Unit for Pfizer, Inc

§ Clinical focus on development of therapies for neurodegenerative disorders§ Held positions at Sanofi-Synthelabo and Ciba-Geigy Pharmaceuticals

Name

Anthony Giovinazzo

Richard Gregory

Bill Wyman

Johannes Roth

Pat Kirwin

33

Independent board of directors

31

Prior ExperienceYears of Experience25+

25+

15+

§ President and CEO of Sunovion CNS Development Canada ULC

§ President, CEO and a Director of Cynapsus Therapeutics from 2009 to 2016 and one of the three original inventors and patent holders of the company’s Parkinson’s focused technology

40+

§ Chief Scientific Officer & Executive VP for Research at ImmunoGen

§ Held a variety of roles at Genzyme and Sanofi-Genzyme, including Vice President for Gene Therapy, Head of Corporate Research and Head of R&D

§ Co-founded the management consulting firm, Oliver Wyman & Co

§ Former President of the Management Consulting Group called Booz Allen and Hamilton

§ Founding director and partner at FiveT Capital Holding AG§ A board member of Insilico Biotechnology AG

§ Senior partner at Kirwin LLP§ Advises and represents businesses in a range of industries and

sizes from local to multinational30+

Name

Scientific Advisory Board

32

Prior ExperienceYears of Experience

Todd Golde, MD, PhD

Lary Walker, PhD

Bill Mobley, MD, PhD

Director of the Center for Translational Research in Neurodegenerative Disease at the University of Florida

Associate Professor of Neurology and Research Professor at Emory University Yerkes National Primate Research Center

Dean for Neurosciences Initiatives, Distinguished Professor of Neurosciences, and Florence Riford Chair for Alzheimer Disease at the University of California, San Diego

20+

25+

20+

Sharon Cohen, MD 20+ Medical Director & Principal Investigator of Toronto Memory ProgramFRCPC in neurology from Royal College of Physicians of Canada and a fellowship in Behavioural Neurology from the University of Toronto

Rudy Tanzi, PhD 20+ Professor of Neurology at Harvard University, Vice Chair of Neurology, Director of Genetics & Aging Research Unit, Co-Director McCance Center for Brain Health at Mass General Hospital

C. Warren Olanow, MD 25+ Previous Henry P & Georgette Goldschmidt Professor & Chairman, Department of Neurology at Mount Sinai School of Medicine, presently Professor Emeritus Department of Neurology & Department of Neuroscience, CEO of CLINTREX

Affiliations

Andre Strydom, MD, PhD Professor Institute of Psychiatry, Psychology and Neuroscience at King’s College London Honorary Consultant psychiatrist, South London and the Maudsley NHS Foundation Trust

25+

José Molinuevo, MD, PhD 20+ Scientific Director, Alzheimer Prevention Program at Barcelonaβeta Brain Research Center, Barcelona SpainAssociate Professor, Pompeu Fabra University, Barcelona, Spain

Hans Frykman, MD, PhD 20+ Clinical assistant professor of medicine at the University of British ColumbiaCEO and Medical Director of BC Neuroimmunology Lab (BCNI)

Thank You

Eugene Williams, Executive Chairmaneugene.williams@promisneurosciences.com+1 (617) 460-0978

Website: www.promisneurosciences.comTwitter: https://twitter.com/ProMISincLinkedIn:https://www.linkedin.com/company/promis-neurosciences

Please feel free to contact us with any additional questions.

Elliot Goldstein, MD, CEOelliot.goldstein@promisneurosciences.com+1 (415) 341-5783

35